期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 68, 期 9, 页码 2164-2169出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkt135
关键词
electrocardiographic abnormalities; triazole drugs; posaconazole; ravuconazole; nifurtimox
资金
- FONDECYT [1120382, 1100768]
To evaluate cases of chronic Chagas disease for the long-term effects of treatment with itraconazole on Trypanosoma cruzi infections and the regression or development of ECG abnormalities. In March 1992, we treated 46 patients with chronic Chagas disease with 6 mg/kg/day of itraconazole for 120 days in a blind evaluation. The patients came from an area of Chile where the disease was endemic and were checked for ECG abnormalities and with xenodiagnosis (XD) or real-time XD-quantitative PCR (XD-qPCR) for Trypanosoma cruzi infection before treatment and once a year for 20 years. Twenty-one patients proved to be uninfected after 20 years and 15 of the patients had a normal ECG. Of the latter cases, 32.6 could be considered cured, although all of them had positive serology. Itraconazole prevents the development of ECG abnormalities, because after 20 years of treatment only 10.86 of patients developed ECG abnormalities (Z1.70, P0.046). XD-qPCR performed on 16 patients demonstrated 10 cases with 1.42 parasites/mL: eight with 1 parasite/mL, one with 1.42 parasites/mL and one with 1.01 parasites/mL. Five patients had more than 11.75 parasites/mL, all of them with a positive XD; these cases correspond to therapy failure, since re-infection was ruled out. In one case, XD-qPCR did not present amplification. Itraconazole is useful in the treatment of chronic Chagas disease as it prevented the development of ECG abnormalities and cured 32.6 of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据